Can the Shingrix (herpes zoster vaccine) vaccine cause shingles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

No, the Shingrix vaccine cannot cause shingles. Shingrix is a non-live, recombinant vaccine that contains only a protein from the varicella-zoster virus, not the virus itself. Since it doesn't contain any live virus, it's impossible for the vaccine to cause shingles. Shingrix works by stimulating your immune system to produce antibodies against the varicella-zoster virus, which helps protect you from developing shingles. Some people may experience side effects after vaccination, including pain, redness, or swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, or upset stomach, but these are immune responses to the vaccine, not shingles. These side effects typically resolve within 2-3 days.

The vaccine's effectiveness has been demonstrated in several studies, including a cohort study among Medicare Part D community-dwelling beneficiaries aged >65 years, which found a vaccine effectiveness of 70.1% (95% confidence interval [CI], 68.6-71.5) and 56.9% (95% CI, 55.0-58.8) for 2 and 1 doses, respectively 1. Shingrix is recommended for adults 50 years and older and is given as a two-dose series, with the second dose administered 2-6 months after the first dose to provide optimal protection against shingles. The vaccine has been shown to be effective in preventing herpes zoster and postherpetic neuralgia, with a significantly better efficacy compared to the live zoster vaccine (Zostavax) 2, 3.

Key points to consider when administering the Shingrix vaccine include:

  • The vaccine is not contraindicated in immunocompromised individuals and is preferred over a live attenuated HZ vaccine in immunocompetent individuals 2
  • The vaccine has been shown to be effective in patients with autoimmune or immunosuppressive conditions 1
  • The vaccine's effectiveness is not significantly lower for beneficiaries aged >80 years, for second doses received at ≥180 days, or for individuals with autoimmune conditions 1
  • The vaccine is well-tolerated, with most solicited adverse reactions being transient and mild to moderate in severity 2

References

Research

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.